266 related articles for article (PubMed ID: 17469093)
1. Will targeting B cells be the answer for Sjögren's syndrome?
Looney RJ
Arthritis Rheum; 2007 May; 56(5):1371-7. PubMed ID: 17469093
[No Abstract] [Full Text] [Related]
2. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
[TBL] [Abstract][Full Text] [Related]
3. Infliximab and primary Sjogren's syndrome: comment on the article by Mariette et al.
Fresko I; Seyahi E; Yurdakul S
Arthritis Rheum; 2004 Dec; 50(12):4077; author reply 4077-8. PubMed ID: 15593208
[No Abstract] [Full Text] [Related]
4. Rituximab therapy in primary Sjögren's syndrome.
Alcântara C; Gomes MJ; Ferreira C
Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of Sjogren's syndrome with rituximab.
Touma Z; Sayad J; Arayssi T
Scand J Rheumatol; 2006; 35(4):323-5. PubMed ID: 16882600
[No Abstract] [Full Text] [Related]
6. The therapy of Sjogren's syndrome: a review.
Coaccioli S; Giuliani M; Puxeddu A
Clin Ter; 2007; 158(5):453-6. PubMed ID: 18062353
[TBL] [Abstract][Full Text] [Related]
7. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles.
Ettefagh L; Nedorost S; Mirmirani P
Arch Dermatol; 2004 Aug; 140(8):1012. PubMed ID: 15313825
[No Abstract] [Full Text] [Related]
8. Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF.
Carubbi F; Cipriani P; Di Benedetto P; Ruscitti P; Alunno A; Gerli R; Giacomelli R
Clin Exp Rheumatol; 2016; 34(6):1123-1124. PubMed ID: 27494407
[No Abstract] [Full Text] [Related]
9. [Sjögren's syndrome: a new approach to treatment].
Rossier V; Bart PA; Spertini F
Rev Med Suisse; 2012 Apr; 8(337):843-7. PubMed ID: 22594008
[TBL] [Abstract][Full Text] [Related]
10. B cell depletion therapy in rheumatic disease.
Edwards JC; Cambridge G; Leandro MJ
Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):915-28. PubMed ID: 16980214
[TBL] [Abstract][Full Text] [Related]
11. Aquaporins in primary Sjögren's syndrome: comment on the articles by Steinfeld et al.
Waterman SA; Beroukas D; Hiscock J; Jonsson R; Gordon TP
Arthritis Rheum; 2003 Apr; 48(4):1167-8. PubMed ID: 12687572
[No Abstract] [Full Text] [Related]
12. B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.
Cornec D; Devauchelle-Pensec V; Tobón GJ; Pers JO; Jousse-Joulin S; Saraux A
J Autoimmun; 2012 Sep; 39(3):161-7. PubMed ID: 22749831
[TBL] [Abstract][Full Text] [Related]
13. Infliximab in primary Sjögren's syndrome: one-year followup.
Steinfeld SD; Demols P; Appelboom T
Arthritis Rheum; 2002 Dec; 46(12):3301-3. PubMed ID: 12483735
[TBL] [Abstract][Full Text] [Related]
14. Issues related to clinical trials of oral and biologic disease-modifying agents for Sjögren's syndrome.
Carsons SE
Rheum Dis Clin North Am; 2008 Nov; 34(4):1011-23, x. PubMed ID: 18984419
[TBL] [Abstract][Full Text] [Related]
15. Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients.
Fauchais AL; Ouattara B; Gondran G; Lalloué F; Petit D; Ly K; Lambert M; Launay D; Loustaud-Ratti V; Bezanahari H; Liozon E; Hachulla E; Jauberteau MO; Vidal E; Hatron PY
Rheumatology (Oxford); 2010 Jun; 49(6):1164-72. PubMed ID: 20299380
[TBL] [Abstract][Full Text] [Related]
16. 2-chloro-2'-deoxyadenosine in the treatment of Sjögren's syndrome-associated B cell lymphoproliferation.
Voulgarelis M; Petroutsos G; Moutsopoulos HM; Skopouli FN
Arthritis Rheum; 2002 Aug; 46(8):2248-9. PubMed ID: 12209533
[No Abstract] [Full Text] [Related]
17. [Cranial pachymeningitis and primary Sjögren's syndrome].
Abouzaid CH; Kissani N; Essaadouni L
Rev Neurol (Paris); 2011 Apr; 167(4):348-51. PubMed ID: 21420701
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of a patient with primary Sjögren's syndrome with Rituximab.
Ring T; Kallenbach M; Praetorius J; Nielsen S; Melgaard B
Clin Rheumatol; 2006 Nov; 25(6):891-4. PubMed ID: 16283417
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.
Pollard RP; Abdulahad WH; Vissink A; Hamza N; Burgerhof JG; Meijer JM; Visser A; Huitema MG; Spijkervet FK; Kallenberg CG; Bootsma H; Kroese FG
Ann Rheum Dis; 2013 Jan; 72(1):146-8. PubMed ID: 22851468
[No Abstract] [Full Text] [Related]
20. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study.
Abdulahad WH; Meijer JM; Kroese FG; Meiners PM; Vissink A; Spijkervet FK; Kallenberg CG; Bootsma H
Arthritis Rheum; 2011 Apr; 63(4):1116-23. PubMed ID: 21225693
[No Abstract] [Full Text] [Related]
[Next] [New Search]
